Drug Transporter (DT) Information

General Information of DT
DT ID DTD0012
Gene Name ABCC3
Protein Name Multidrug resistance-associated protein 3
Gene ID
8714
UniProt ID
O15438
TCDB ID
3.A.1.208.9
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6UY0_A

Identity: 57.19%

Minimized Score: -3311.772 kcal/mol

Detail: Structure Info

Synonyms ABC31; ABCC3; ATP-binding cassette sub-family C member 3; CMOAT2; Canalicular multispecific organic anion transporter 2; EST90757; MLP2; MOAT-D; MRP3; Multi-specific organic anion transporter D
DT Family ATP-Binding Cassette (ABC) Superfamily
Drug Conjugate Transporter (DCT) Family (ABCC)
Tissue Specificity Mainly expressed in the liver. Also expressedin small intestine, colon, prostate, testis, brain and at a lowerlevel in the kidney.
Function This transporter may act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes.
Disease(s) Allergic rhinitis [ICD-11: CA08.0]
Colorectal cancer [ICD-11: 2B91]
Hypercholesterolemia [ICD-11: 5C80.0]
Kaposi's sarcoma [ICD-11: 2B57]
Leukemia [ICD-11: 2A60-2B33]
Chronic pain [ICD-11: MG30]
Endogenous Substrate(s) Canicular organoanions; GSH-X; Sulfate-X; Bile acids; Bilirubin-glucuronides; Epoposide glucuronide; Estradiol 17-beta-D-glucuronide; Glycocholate; Leukotriene C4
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          17 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Cefadroxil
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [1]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [2]
Efavirenz
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [3]
Etoposide
 Approved Drug Info Testicular cancer 2C80 [4]
Etravirine
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [5]
Ezetimibe
 Approved Drug Info Hypercholesterolemia 5C80.0 [6]
Fexofenadine
 Approved Drug Info Allergic rhinitis CA08.0 [7]
Fluorouracil
 Approved Drug Info Stomach cancer 2B72 [8]
Folic acid
 Approved Drug Info Vitamin deficiency 5B55-5B7Z [9]
Glibenclamide
 Approved Drug Info Diabetes 5A10-5A14 [10]
Glycyrrhizin
 Approved Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [11]
Leucovorin
 Approved Drug Info Colorectal cancer 2B91 [9]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [12]
Morphine
 Approved Drug Info Chronic pain MG30 [13]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [14]
Technetium (99MTC) mebrofenin
 Approved Drug Info Imaging of liver and gallbladder XD47Y1 [15]
Teniposide
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [16]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            4 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Glycocholic acid
 Phase 3 Drug Info Bile acid synthesis defect 5C52.11 [17]
Trabectedin
 Phase 3 Drug Info Ovarian cancer 2C73 [18]
Cholyl lysyl fluorescein
 Phase 2 Drug Info Hepatitis virus infection 1E5Z [19]
Glutathione-S-S-glutathione
 Phase 2 Drug Info Ovarian cancer 2C73 [20]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Epipodophyllotoxins
 Preclinical Drug Info Molluscum contagiosum infection 1.00E+76 [16]
Monomethyl-auristatin-E
 Preclinical Drug Info Cancer 2A00-2F9Z [14]
Scutellarin
 Preclinical Drug Info Cerebrovascular ischaemia 8B1Z [21]
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [22]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [22]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Glucuronide
5281877
EM Info Identified using Mrp3 knockout mice [23]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            7 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Cefadroxil Approved Drug Info Spodoptera frugiperda 21 (Sf21) cells-MRP3 Km = 2.5 microM [1]
Etoposide Approved Drug Info Spodoptera frugiperda (Sf9) cells-MRP3 Km = 11.4 microM [16]
Folic acid Approved Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 1960 microM [9]
Leucovorin Approved Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 1740 microM [9]
Methotrexate Approved Drug Info Breast carcinoma cell line (MCF7)-MRP3 Km = 910 microM [12]
Methotrexate Approved Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 620 microM [9]
Methotrexate Approved Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 776 microM [24]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            4 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Sodium taurocholate Preclinical Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 30 microM [22]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 25.6 microM [24]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-MRP3 Km = 29 microM [22]
Estradiol-17beta-glucuronide Investigative Drug Info Spodoptera frugiperda (Sf9) cells-MRP3 Km = 17.7 microM [16]
References
1 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
2 Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006 Apr;27(5):447-86.
3 Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
4 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
5 Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4.
6 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
7 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
8 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
9 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
10 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
11 The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007 Dec;31(6):1465-72.
12 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
13 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
14 Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
15 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
16 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
17 Measurement of transport activities of bile acids in human multidrug resistance-associated protein 3 using liquid chromatography-tandem mass spectrometry. Anal Sci. 2010;26(3):317-23.
18 ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity. Clin Cancer Res. 2009 Dec 15;15(24):7616-7623.
19 The emerging role of transport systems in liver function tests. Eur J Pharmacol. 2012 Jan 30;675(1-3):1-5.
20 MRP2 and 3 in health and disease. Cancer Lett. 2006 Mar 8;234(1):51-61.
21 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
22 Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
23 Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol. 2006 Apr;44(4):768-75.
24 Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000 Sep 1;60(17):4779-84.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.